EUCTR2007-002583-10-DE进行中（未招募）不适用
A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Ramipril in Subjects With Essential Hypertension
Takeda Global Research & Development Centre (Europe) Ltd.0 个研究点目标入组 1,200 人开始时间: 2008年12月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- The subject has essential hypertension (defined as SBP between 150 and 180 mmHg, inclusive, at Randomization).
- •- The subject is a man or non pregnant woman, aged 18 years or older.
- •- The subject is capable of understanding and complying with protocol requirements.
- •- The subject signs a written, informed consent form prior to the initiation of any study procedures.
- •- A female subject of childbearing potential who is sexually active agrees to use adequate contraception from screening throughout the duration of the study. Women not of child-bearing potential are defined as those who have been surgically sterilized (hysterectomy, oophorectomy, tubal ligation) or who are postmenopausal (defined as at least 2 years since last regular menses).
- •- The subject has clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory at Screening or the results are deemed not clinically significant for inclusion into this study by the investigator.
- •- The subject is willing to discontinue current antihypertensive medications at Screening Day -21. If the subject is on amlodipine prior to screening, the subject is willing to discontinue this medication at Screening Day -28.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- The subject has an SBP greater than 180 mmHg or DBP greater than 114 mmHg at Randomization.
- •- The subject is taking or expected to take an excluded medication as described in the Excluded Medications section.
- •- The subject has known hypersensitivity to ARBs and/or ACE inhibitors.
- •- The subject has a recent history (within the last 6 month) of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack.
- •- The subject has clinically significant cardiac conduction defects (eg, third-degree atrioventricular block, left bundle branch block, sick sinus syndrome, atrial fibrillation or flutter).
- •- The subject has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
- •- The subject has secondary hypertension of any etiology (eg, renovascular disease, pheochromocytoma, Cushing’s syndrome).
- •- The subject is noncompliant (less than 70% or greater than 130%) with study medication during placebo run-in period.
- •- The subject has severe renal dysfunction or disease (based on calculated creatinine clearance <30 mL/min/1.73 m² at Screening).
- •- Subject has known or suspected unilateral or bilateral renal artery stenosis.
- •- The subject has a history of drug or alcohol abuse within the past 2 years.
- •- The subject has a previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. (This criterion does not apply to those subjects with basal cell or stage I squamous cell carcinoma of the skin).
- •- The subject has type 1 or poorly controlled type 2 diabetes mellitus (hemoglobin A1c [HbA1c] >8.0%) or is taking insulin.
- •- The subject has hyperkalemia as defined by the central laboratory normal reference range at Screening.
- •- The subject has an upper arm circumference less than 24 cm or greater than 42 cm.
- •- The subject works night (third) shift (defined as 11 PM to 7 AM).
- •- The subject has an alanine aminotransferase (ALT) level at Screening of greater than 2.5 times the upper limit of normal (ULN), active liver disease, or jaundice.
- •- The subject is unwilling or unable to comply with the protocol or scheduled appointments.
- •- The subject is unable to understand verbal or written English or any other language for which a certified translation of the approved informed consent is available.
- •- The subject is a study site employee, or is an immediate family member (ie, spouse, parent, child, and sibling) of a study site employee who is involved in conduct of this study.
- •- If female, the subject is pregnant, intends to become pregnant during the course of the study, or is lactating.
- •- The subject currently is participating in another investigational study or has participated in an investigational study within 30 days prior to Screening.
- •- The subject has any other serious disease or condition at Screening or Randomization that would compromise subject safety, might affect life expectancy, or make it difficult to successfully manage and follow the subject according to the protocol.
- •- The subject has been randomized in a previous TAK-491 study.
研究者
相似试验
进行中（未招募）
不适用
A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Ramipril in Subjects With Essential HypertensioEUCTR2007-002583-10-NLTakeda Global Research & Development Centre (Europe) Ltd.1,200
进行中（未招募）
1 期
A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Ramipril in Subjects With Essential HypertensioAccording to the World Health Organization, hypertension (high blood pressure) is the most common attributable cause of preventable death in developed nations. When uncontrolled, hypertension is associated with greatly increased risk of cardiovascular disease, cerebrovascular disease, and renal failure.MedDRA version: 9.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2007-002583-10-SKTakeda Global Research & Development Centre (Europe) Ltd.1,200
已完成
不适用
Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential HypertensioPER-027-08TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC.,
进行中（未招募）
1 期
A Study Comparing MabionCD20 (new Rituximab biosimilar) with MabThera (reference Rituximab from EU) and Rituxan (reference Rituximab from US) in Patients with Rheumatoid ArthritisModerate-to-severe rheumatoid arthritisMedDRA version: 23.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2020-002765-34-BEMabion S.A.280
进行中（未招募）
不适用
A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Ramipril in Subjects With Essential HypertensioEUCTR2007-002583-10-BGTakeda Global Research & Development Centre (Europe) Ltd.1,200